Hydron Technologies, Inc. Reports Third Quarter Results and Announces Completion of Private Placement Financing

Hydron Technologies, Inc. Reports Third Quarter Results and Announces Completion
of Private Placement Financing 


POMPANO BEACH, Fla., Nov. 13  /PRNewswire-FirstCall/ -- Hydron Technologies,
Inc.  (BULLETIN BOARD: HTEC)  announced today that the Company had net sales of
$295,423 and a net loss of $163,572 ($.02 per share) for the quarter ended
September 30, 2003, as compared to net sales of $305,281 and a net loss of
$204,049 ($.04 per share) for the quarter ended September 30, 2002. The Company
also reported net sales of $860,641 and a net loss of $528,959 ($.08 per share)
for the nine months ended September 30, 2003, as compared to net sales of
$1,187,686 and a net loss of $596,547 ($.12 per share) for the nine months ended
September 30, 2002.

Catalog net sales for the three months ended September 30, 2003, were $244,635,
a decrease of $44,085, or 15% from catalog net sales of $288,720 for the three
months ended September 30, 2002. Catalog sale for the nine-month period ended
September 30, 2003 were $789,506, a decrease of $130,285, or 14%, from Catalog
net sales of $919,791 for the nine months ended September 30, 2002. The decrease
in catalog net sales was primarily the result of fewer promotions to existing
customers.

Non-catalog net sales, including television retailers, contract sales and
international, for the three months ended September 30, 2003 were $50,788, an
increase of $34,227, or 207%, from non-catalog net sales of $16,561 for the
three months ended September 30, 2002. Non-catalog sales for the nine-month
period ended September 30, 2003 were $71,135, a decrease of $196,760, or 73%,
from non-catalog net sales of $267,895 for the nine months ended September 30,
2002. This decrease is primarily due to timing of private label orders and a
decrease in sales to retail stores.

The Company's overall gross profit margin for the three months ended September
30, 2003 was 74%, as compared to 81% for the three months ended September 30,
2002. The decrease in gross profit margins for the period reflects a shift in
product mix as non-catalog sales, which have lower margins, represent a larger
portion of the sales mix versus the same quarter last year.

Total operating expenses for the three months ended September 30, 2003 were
$381,030, a decrease of $69,527, or 15%, from total operating expenses of
$450,557 for the three months ended September 30, 2002. The decrease was
principally due to decreased royalty expense, lower depreciation, sales
commissions, warehousing costs and administrative expenses.

The net loss for the three months ended September 30, 2003 was $163,572, a
decrease of $40,477, or 20%, as compared to a net loss of $204,049 for the three
months ended September 30, 2002. The decrease in the net loss resulted from
stringent cost controls and the factors discussed above.

Hydron also announced today the completion of a non-brokered Private Placement
financing raised $1,105,000 to finance the development of its tissue oxygenation
technology.  The Company has accepted Subscription Agreements for 2,210,000
shares of Common and 2,210,000 Warrants to purchase an equal number of shares
during the next five years, at an exercise price of $1.00 per share at a unit
cost of $.50.  On October 15, 2003 the Company paid the non-interest bearing
bridge loan from the Company Chairman and another Director and the Directors
reinvested the proceeds into the Private Placement offering.

The proceeds of the placement will be added to the Company's working capital and
enable Hydron Technologies to expand its research and product development
program related to Hydron's patent pending skin and tissue oxygenation
technology. The Company expects the U.S. Patent Office to issue the patent
within the next 30 days.

Mr. Terrence McGrath, the Company's Chief Operating Officer, said, "Hydron's
primary focus is the advancement of its oxygenation technology. The oxygenation
technology enables the infusion of oxygen, using microbubble laden fluids, into
skin and tissue topically, without using the bloodstream. This unique technology
provides Hydron the opportunity to develop products ranging from medical
treatments for wounds and burns and development of over-the- counter products
for diaper rash, scar reduction and cosmeceutical skin care products.

Mr. McGrath stated, "With the closing of the private placement, Hydron is now in
a position to accelerate its research program to include development of
marketable products and efficacy testing of medical treatments.  Hydron will
also seek strategic alliances to pursue certain medical applications associated
with the oxygen project.

Hydron Technologies, Inc. markets a broad range of personal care products and is
committed to the research and development of products and medical applications
associated with its proprietary tissue oxygenation technology. The Company
markets its skin care products through Hydron's direct-to-consumer catalog and
on the Internet at http://www.hydron.com/. Catalogs are available by calling
1-800-4-HYDRON (1-800-449-3766).

Except for historical information, all of the expectations and assumptions
contained in the foregoing are forward-looking statements involving risks and
uncertainties. For additional information regarding the risks associated with
the Company's business, refer to Hydron Technologies, Inc. reports filed with
the SEC. 

DATASOURCE: Hydron Technologies, Inc.



CONTACT:  Terrence S. McGrath, COO of Hydron Technologies,

[phone]



Web site:  http://www.hydron.com/ 

Copyright